Results presented in this study suggest that administration of TTFE for 21 days normalized STZ‐induced hyperglycemia and its associated dyslipidemia by mechanisms involving enhanced plasma insulin secretion which could possibly stimulate cellular glucose uptake; inhibition of α‐amylase activity thus regulating the release of glucose into the blood and regulation of hepatic lipid synthesis via inhibition of HMG‐CoA reductase activity in rats. The gene discussed is INS; the disease is metabolic syndrome.